NCT01086540: A reported trial by National Institute of Allergy and Infectious Diseases (NIAID)
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT01086540 |
|---|---|
| Title | A Randomized, Double-Blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) for the Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH) |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | June 24, 2011 |
| Completion date | June 5, 2018 |
| Required reporting date | June 5, 2021, midnight |
| Actual reporting date | June 30, 2020 |
| Date last checked at ClinicalTrials.gov | March 28, 2025 |
| Days late | None |